Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical enti...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

1 Adelaide Street East, Suite 801, Toronto, Canada

Rambler1111 Sep. 14 at 6:33 PM

$QNTM

0 · Reply

LewisDaKat Sep. 14 at 6:30 PM

$QNTM NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating 'Rare Moment' in MS Research https://marketwirenews.com/stock/qntm/news/networknewsaudio-announces-audio-press-release-apr-d-8618913083084166.html?utm_source=stocktwits

0 · Reply

NetworkNewsWire Sep. 14 at 5:20 PM

NetworkNewsBreaks – $QNTM Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND https://nnw.fm/E5nJp

0 · Reply

Invescent Sep. 14 at 5:54 AM

Low-cap catalyst watch for Monday $FFAI Float: ~ 3.85M Short: ~752K Short float: 19.5% Catalyst: Sept. 19 robotics launch — 9 new robot devices planned. Very tight float + high SI. $DPRO Public float used for latest SI calc: ~21.9M Short: ~3.76M Short float: 17.2% Catalyst: 5-year Canadian Armed Forces drone contract. 100 systems committed + option for 4,900 more (~C$24.25M option value). $QNTM Float: ~7.49M Short: ~261K Short float: 3.5% Catalyst: FDA clearance to advance Lucid-MS into Phase 2 for multiple sclerosis. $WHWK Float: ~28.6M Short: ~2.98M Short float: 10.4% Catalyst: New WCLC 2026 data supporting PTK7 as a target in lung cancer. Watching for volume Monday

0 · Reply

NetworkNewsWire Sep. 11 at 7:32 PM

InvestorNewsBreaks – $QNTM Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial https://ibn.fm/No4lN

0 · Reply

PrintingGains Sep. 11 at 6:39 PM

$QNTM wont sell at all

0 · Reply

FickleFin Sep. 11 at 5:43 PM

$QNTM 3yrs and still going... 🥴🥴🥴 Reason really why unbuzzd hasnt moved since inception. Never ending with the Continuance over and over. Safety $SHOT doesnt exist anymore and is now $BNKK 🥴🥴🥴 exit liquidity and loopholes

0 · Reply

focafoca99 Sep. 11 at 12:46 PM

$QNTM received FDA clearance to start a Phase 2 trial of its first-in-class MS drug Lucid-MS, a historic first for the mechanism.

0 · Reply

Stock_Catcher Sep. 11 at 12:30 PM

$QNTM Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

0 · Reply

NetworkNewsWire Sep. 10 at 6:29 PM

MissionIRNewsBreaks – $QNTM Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance https://ibn.fm/cU1HO

0 · Reply

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research

Sep 11, 2026, 8:30 AM EDT - 3 days ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Sep 9, 2026, 8:30 AM EDT - 5 days ago

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

Sep 1, 2026, 7:00 PM EDT - 12 days ago

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

2026-08-31T11:10:12.000Z - 14 days ago

Quantum Group initiated with a Buy at Rodman & Renshaw

Aug 21, 2026, 7:00 PM EDT - 23 days ago

Quantum Biopharma Provides Corporate Update

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Aug 10, 2026, 7:00 AM EDT - 5 weeks ago

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Jul 30, 2026, 12:18 AM EDT - 6 weeks ago

Quantum BioPharma Announces Closing of Debt Settlement

Jul 20, 2026, 7:00 PM EDT - 7 weeks ago

Quantum BioPharma Announces Intention to Settle Debt

Jul 7, 2026, 7:00 PM EDT - 2 months ago

Quantum BioPharma Provides Corporate Update

Jun 26, 2026, 8:30 AM EDT - 2 months ago

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Jun 25, 2026, 8:30 AM EDT - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Jun 2, 2026, 8:00 AM EDT - 3 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Jun 2, 2026, 7:40 AM EDT - 3 months ago

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

May 18, 2026, 3:00 AM EDT - 3 months ago

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

May 7, 2026, 7:00 AM EDT - 4 months ago

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Apr 22, 2026, 9:16 AM EDT - 4 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

2026-04-01T12:25:14.000Z - 5 months ago

Quantum BioPharma submits Lucid-21-302 new drug application to the FDA

Apr 1, 2026, 8:02 AM EDT - 5 months ago

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

2026-03-30T12:47:57.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

2026-03-30T12:28:19.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

Mar 30, 2026, 7:50 AM EDT - 5 months ago

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Mar 27, 2026, 8:10 AM EDT - 5 months ago

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status

Mar 23, 2026, 8:24 AM EDT - 5 months ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Mar 20, 2026, 7:35 PM EDT - 5 months ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Dec 23, 2025, 8:00 AM EST - 8 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Dec 10, 2025, 8:00 PM EST - 9 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

2025-12-01T12:15:18.000Z - 9 months ago

Quantum BioPharma announces airing of news segment on manipulation lawsuit

Nov 27, 2025, 4:00 PM EST - 9 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 26, 2025, 9:30 AM EST - 9 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

2025-11-07T12:12:42.000Z - 10 months ago

Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year

2025-11-07T12:11:35.000Z - 10 months ago

Quantum BioPharma sees cash runway beyond March 2027

Nov 7, 2025, 7:00 AM EST - 10 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 10 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 10 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 10 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

2025-10-20T12:40:40.000Z - 10 months ago

Quantum BioPharma announces expiration of warrants held by hedge funds

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 9, 2025, 6:00 PM EDT - 11 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 11 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Oct 3, 2025, 7:00 AM EDT - 11 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Oct 2, 2025, 7:57 AM EDT - 11 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Oct 1, 2025, 7:50 AM EDT - 11 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Sep 29, 2025, 7:40 AM EDT - 11 months ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 11 months ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 11 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 12 months ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 1 year ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 1 year ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 1 year ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Rambler1111 Sep. 14 at 6:33 PM

$QNTM

0 · Reply

LewisDaKat Sep. 14 at 6:30 PM

0 · Reply

NetworkNewsWire Sep. 14 at 5:20 PM

NetworkNewsBreaks – $QNTM Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND https://nnw.fm/E5nJp

0 · Reply

Invescent Sep. 14 at 5:54 AM

0 · Reply

NetworkNewsWire Sep. 11 at 7:32 PM

InvestorNewsBreaks – $QNTM Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial https://ibn.fm/No4lN

0 · Reply

PrintingGains Sep. 11 at 6:39 PM

$QNTM wont sell at all

0 · Reply

FickleFin Sep. 11 at 5:43 PM

0 · Reply

focafoca99 Sep. 11 at 12:46 PM

$QNTM received FDA clearance to start a Phase 2 trial of its first-in-class MS drug Lucid-MS, a historic first for the mechanism.

0 · Reply

Stock_Catcher Sep. 11 at 12:30 PM

$QNTM Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

0 · Reply

NetworkNewsWire Sep. 10 at 6:29 PM

MissionIRNewsBreaks – $QNTM Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance https://ibn.fm/cU1HO

0 · Reply

ZacksResearch Sep. 10 at 6:27 PM

$QNTM just cleared a major MS milestone — but can Lucid-MS deliver? 🔥 Quantum BioPharma received FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug candidate aimed at protecting and potentially repairing the myelin sheath. The milestone has already drawn a fresh buy rating from Wall Street analysts. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-39531&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_39531

0 · Reply

Cons228 Sep. 10 at 6:11 PM

$QNTM one doesn’t need to check the news … you simply can see there are great news just looking at the dropping chart. If it drops like this, there are gigantic news

1 · Reply

NetworkNewsWire Sep. 10 at 1:12 PM

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market $QNTM $NVS $MRK $TGTX $BMY https://ibn.fm/A7zHr

1 · Reply

MrTicker Sep. 10 at 12:30 PM

$QNTM Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market GLOBENEWSWIRE 7:30 AM ET 9/10/2026

1 · Reply

FickleFin Sep. 10 at 12:04 PM

$QNTM pump and dump. Exit liquidity. Why do you think Baloney is trying so hard...

0 · Reply

Woodman7 Sep. 9 at 2:47 PM

$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”

0 · Reply

MrTicker Sep. 9 at 2:08 PM

$QNTM $4+ on tap

1 · Reply

NetworkNewsWire Sep. 9 at 1:58 PM

BioMedNewsBreaks — $QNTM $QNTM.CN Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial https://ibn.fm/dwwiP

0 · Reply

FickleFin Sep. 9 at 1:06 PM

$QNTM $GNS $GME this is literally their PEA story all over again. The hype the bunk press releases. Partnership with 3rd party to accelerate studies. Mass pumping, mass paid promo. Then you have baloney that adds to the mess. What ever happened to the naked short lawsuit? They sure went quiet with that. All this company is.. is noise and press releases. Only lemmings invest in shitcos

0 · Reply

MrTicker Sep. 9 at 12:32 PM

$QNTM Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment GLOBENEWSWIRE 7:30 AM ET 9/9/2026

0 · Reply

Stock_Catcher Sep. 9 at 12:32 PM

$QNTM Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

0 · Reply

parcha Sep. 8 at 5:45 PM

https://www.cnbc.com/2026/09/08/stocks-making-the-biggest-moves-midday-amgn-qcom-expe-crwv.html $QBTS $RGTI $QNTM Quantum computing stocks – The quantum computing sector rallied after the U.S. agreed to take minority equity stakes in several companies as part of a $300 million CHIPS Act deal. The investments are in D-Wave Quantum, Rigetti Computing and Quantinuum. D-Wave gained more than 7%, Rigetti rose 4% and Quantinuum added 3%.

1 · Reply

Market Cap	20.48M
Revenue (ttm)	0.00
Net Income (ttm)	-26.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	173,257
Avg Vol	189,984
Day's Range	N/A - N/A
Shares Out	6.40M
Stochastic %K	35%
Beta	0.45
Analysts	Strong Sell
Price Target	$21.75